Latest Clinical Development News

Page 11 of 57
Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.
Ada Torres
Ada Torres
3 July 2026
Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.
Victor Sage
Victor Sage
2 July 2026
Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.
Ada Torres
Ada Torres
2 July 2026
Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.
Ada Torres
Ada Torres
1 July 2026
AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.
Ada Torres
Ada Torres
1 July 2026
Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.
Ada Torres
Ada Torres
30 June 2026
Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.
Ada Torres
Ada Torres
30 June 2026
Recce Pharmaceuticals secured A$4 million through an institutional placement and launched a Share Purchase Plan to raise up to an additional A$4 million, bolstering funds for commercial licensing and ongoing clinical programs.
Ada Torres
Ada Torres
26 June 2026
Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.
Ada Torres
Ada Torres
16 June 2026
Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.
Ada Torres
Ada Torres
16 June 2026
CLINUVEL Pharmaceuticals has lodged its Form 20-F with the U.S. SEC, seeking to elevate its American Depository Receipt program to a Nasdaq-listed American Depository Share, aiming to boost visibility and liquidity without raising capital.
Victor Sage
Victor Sage
16 June 2026
Neurizon Therapeutics has dosed over 50% of participants in the HEALEY ALS Platform Trial's Regimen I, exceeding recruitment expectations after expanding the cohort from 160 to 240 patients. The accelerated pace puts the company on track for last patient dosing in Q2 2027 and topline results by early Q3 2027.
Ada Torres
Ada Torres
12 June 2026

Browse the archive

Full archive